IMMUNITYBIO, INC. (IBRX) Free cash flow 2016–2025
IMMUNITYBIO, INC. (IBRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$308.8MFY2025 · since FY2016: -$45.2M → -$308.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$308.8M | +22.4% |
| FY2024 | -$398.1M | -0.2% |
| FY2023 | -$397.3M | +4.4% |
| FY2022 | -$415.7M | -35.0% |
| FY2021 | -$308.0M | -77.6% |
| FY2020 | -$173.4M | -10.9% |
| FY2019 | -$156.4M | -104.5% |
| FY2018 | -$76.5M | +8.5% |
| FY2017 | -$83.6M | -85.1% |
| FY2016 | -$45.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice